Considering that RNase1 and other RNases were significantly associated with overall survival in large patient cohorts in different cancer types21–23, RNase1 was the top candidate for further investigation due to its upregulation in non-responders receiving Nivolumab and its unknown function in tumor immunity. This evidence concerns the gene RNASE1 and cancer.